Payment overview · 2025
General Payments
$4,570.60
202 reported records · 25 companies
Healthcare provider profile · identity verified
Greg E Eudy, MD PC
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · BIRMINGHAM, AL · NPI 1154426872
Verified facts
What the public records show
CMS Open Payments records show Greg E Eudy, MD PC received $4,570.60 in general payments during 2025 across 202 reported records.
ABBVIE INC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Benlysta, Kevzara, Kineret, Orencia, Rinvoq, Strensiq, Tymlos, Xeljanz.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rinvoq by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STRENSIQ as an associated drug or biological on 6569 records involving 3831 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Strensiq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Enbrel by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Orencia by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kevzara by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Actemra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Remicade by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Simponi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Stelara by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xeljanz by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Tymlos by this doctor in 2024.
SOBI, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kineret as an associated drug or biological on 1818 records involving 1208 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kineret by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $823.19 | 18.0% | 35 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $611.03 | 13.4% | 28 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $545.70 | 11.9% | 28 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $413.82 | 9.1% | 17 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $365.80 | 8.0% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $338.50 | 7.4% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $330.18 | 7.2% | 14 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $215.30 | 4.7% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.17 | 3.5% | 8 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $127.86 | 2.8% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.10 | 1.9% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.09 | 1.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $75.23 | 1.6% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $58.53 | 1.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.20 | 1.1% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $47.06 | 1.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $39.21 | 0.9% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $36.59 | 0.8% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $36.33 | 0.8% | 2 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.79 | 0.7% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $24.90 | 0.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.36 | 0.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.15 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.29 | 0.3% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $14.22 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,570.60 | 202 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $573.78 | 25 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $416.78 | 21 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $365.80 | 19 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $338.50 | 10 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $283.34 | 12 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $257.32 | 11 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $249.41 | 10 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $245.30 | 9 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $215.30 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $211.88 | 12 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $190.12 | 7 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $160.17 | 8 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $127.86 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $118.74 | 9 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $80.09 | 3 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $75.23 | 3 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $72.86 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $60.39 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $58.57 | 3 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $58.53 | 3 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $54.38 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.20 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $47.22 | 4 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $36.33 | 2 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $32.98 | 1 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $30.79 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $28.63 | 2 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| SOVUNA Normalized: sovuna |
Drug | ANI Pharmaceuticals, Inc. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kineret kineret |
2025 | Kineret | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 109 | exact normalized | Medicare Part D |
| STRENSIQ strensiq |
2025 | Strensiq | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 99 | exact normalized | Medicare Part D |
| XELJANZ xeljanz |
2025 | Xeljanz | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
109 | 14 |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | STRENSIQ open payments reported associated product |
CMS Open Payments — General Payments 6569 supporting records · 3831 recipient NPIs · example record 1202912932 |
Strensiq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 2 Part D rows |
33 | not aggregated across multiple Part D rows |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
| SOBI, INC Exact reporting entity; no affiliate inference |
2025 | Kineret open payments reported associated product |
CMS Open Payments — General Payments 1818 supporting records · 1208 recipient NPIs · example record 1240223689 |
Kineret · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 1729 | 476 |
| Methotrexate | Methotrexate Sodium | 862 | 244 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 806 | 103 |
| Tramadol Hcl | Tramadol Hcl | 733 | 149 |
| Gabapentin | Gabapentin | 589 | 124 |
| Prednisone | Prednisone | 562 | 128 |
| Celecoxib | Celecoxib | 466 | 136 |
| Duloxetine Hcl | Duloxetine Hcl | 376 | 98 |
| Meloxicam | Meloxicam | 356 | 109 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 346 | 37 |
| Pregabalin | Pregabalin | 290 | 48 |
| Sulfasalazine Dr | Sulfasalazine | 248 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 234 | 64 |
| Sulfasalazine | Sulfasalazine | 232 | 60 |
| Allopurinol | Allopurinol | 207 | 58 |
| Methocarbamol | Methocarbamol | 206 | 51 |
| Alendronate Sodium | Alendronate Sodium | 204 | 67 |
| Leflunomide | Leflunomide | 199 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 194 | 37 |
| Methylprednisolone | Methylprednisolone | 185 | 130 |
| Trazodone Hcl | Trazodone Hcl | 175 | 50 |
| Azathioprine | Azathioprine | 172 | 34 |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 169 | 57 |
| Colchicine | Colchicine | 154 | 60 |
| Ropinirole Hcl | Ropinirole Hcl | 152 | 30 |
| Clonazepam | Clonazepam | 139 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 15 |
| Rinvoq | Upadacitinib | 109 | 14 |
| Lidocaine | Lidocaine | 100 | 44 |
| Tymlos | Abaloparatide | 99 | 20 |
| Humira(Cf) Pen | Adalimumab | 86 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 31 |
| Enbrel Sureclick | Etanercept | 76 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 74 | 22 |
| Alprazolam | Alprazolam | 73 | 13 |
| Carisoprodol | Carisoprodol | 68 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 60 | 25 |
| Pilocarpine Hcl | Pilocarpine Hcl | 58 | 18 |
| Folic Acid | Folic Acid | 57 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 54 | 14 |
| Tramadol Hcl Er | Tramadol Hcl | 54 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 14 |
| Promethazine Hcl | Promethazine Hcl | 48 | 12 |
| Baclofen | Baclofen | 46 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 45 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 45 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 44 | 15 |
| Orencia Clickject | Abatacept | 43 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | 12 |
| Nucynta Er | Tapentadol Hcl | 40 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 39 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 12 |
| Ondansetron Odt | Ondansetron | 37 | 17 |
| Actemra | Tocilizumab | 36 | suppressed |
| Buprenorphine | Buprenorphine | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Felodipine Er | Felodipine | 35 | suppressed |
| Teriparatide | Teriparatide | 35 | suppressed |
| Omeprazole | Omeprazole | 34 | 12 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 12 |
| Modafinil | Modafinil | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Kevzara | Sarilumab | 22 | suppressed |
| Olumiant | Baricitinib | 22 | suppressed |
| Strensiq | Asfotase Alfa | 22 | suppressed |
| Xeljanz | Tofacitinib Citrate | 22 | suppressed |
| Orencia | Abatacept/Maltose | 21 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Xtampza Er | Oxycodone Myristate | 16 | suppressed |
| Arcalyst | Rilonacept | 15 | suppressed |
| Enbrel | Etanercept | 15 | suppressed |
| Nucynta | Tapentadol Hcl | 15 | suppressed |
| Rayos | Prednisone | 15 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 14 | suppressed |
| Gralise | Gabapentin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Remicade | Infliximab | 14 | suppressed |
| Simponi | Golimumab | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Belbuca | Buprenorphine Hcl | 13 | suppressed |
| Enbrel Mini | Etanercept | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Plaquenil | Hydroxychloroquine Sulfate | 13 | suppressed |
| Rasuvo | Methotrexate/Pf | 13 | suppressed |
| Benlysta | Belimumab | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Kineret | Anakinra | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Orencia | Abatacept | 12 | suppressed |
| Stelara | Ustekinumab | 12 | suppressed |
| Actemra Actpen | Tocilizumab | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Humira | Adalimumab | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,570.60 · 202 records | ABBVIE INC. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, CRYSVITA, CUTAQUIG, EUFLEXXA, EVENITY, HADLIMA, ILARIS, KEVZARA, KRYSTEXXA, Kineret, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, ORENCIA, OTEZLA, PANZYGA, PEMGARDA, PROLIA, PURIFIED CORTROPHIN GEL, Quzyttir, RELISTOR, RENFLEXIS, RINVOQ, SAPHNELO, SKYRIZI, SOVUNA, STRENSIQ, Sotyktu, TAVNEOS, TREMFYA, Tymlos, UPLIZNA, XELJANZ, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error